← Oncology Approval Tracker

FDA DECISION ·

Yescarta

axicabtagene ciloleucel · Kite Pharma

FDA approvalNew or expanded indicationLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months after it.

LAMPGEN ANALYSIS

Why it matters

The action moves CAR T-cell therapy earlier for patients with primary refractory disease or early relapse.

What research teams should watch

Calculate the first-line-to-relapse interval and coordinate referral before subsequent treatment changes cell collection or timing.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

CAR T-cell studies in relapsed or refractory DLBCL

PRIMARY RECORDS

Sources